Lundbeck and Genmab work on antibodies for central nervous system

10/13/2010 | Reuters

Genmab stands to receive as much as $53.5 million, including $10.4 million upfront, from H. Lundbeck in a deal to develop human antibodies to treat diseases affecting the central nervous system. The collaboration provides Lundbeck access to Genmab's human-antibody technology UltiMab, allowing it "to pursue valuable [central nervous system] targets otherwise not accessible."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX